SCIENTIFIC RATIONALE Clause Samples

SCIENTIFIC RATIONALE. 5. 1 Novel HDL-C raising therapies
SCIENTIFIC RATIONALE. During my 2012 practicum in the Surveillance Department in KSA, I noticed an increase in the number of dengue fever cases in Makkah City, especially among children. In one Makkah study, 24% of the cases occurred among children < 12 years of age [10]. Also, two of my relatives were diagnosed with dengue fever; they were admitted to the hospital. The cost of their care was very high. In addition, the number of cases in the general population continues to increase, even while the MOH invests an enormous amount of money for health education and vector control. To reduce the number of dengue infections in Makkah, the KSA MOH must work to improve and enforce its prevention measures through multiple levels. To do this, it is very important to first understand the changing distribution of dengue infection over time and to identify high-risk groups. This epidemiologic information helps guide the development of proper policies. Dengue fever is a reportable condition and case-based information is collected by the VBDU in the KSA MOH. However, these case records have not been analyzed beyond the production of yearly aggregated reports. Therefore, I analyzed the dengue fever data in Makkah collected by the VBDU from 2008 to 2012 to inform policymakers about any conspicuous trends or at-risk population subgroups.
SCIENTIFIC RATIONALE. Host serum protein biomarkers that indicate a high likelihood for active TB disease represent attractive targets for integration into screening tests. The EDCTP 1-funded African European Tuberculosis Consortium (AE-TBC) has previously investigated host biosignatures in whole blood culture supernatants after overnight stimulation with Mycobacterium tuberculosis (MTB) specific proteins. During this project >1,300 people from high TB prevalence areas (South Africa, Namibia, Malawi, The Gambia, Uganda and Ethiopia) with symptoms suggestive of active TB were recruited and worked up diagnostically with CXR, sputum culture, smear and GeneXpert. One third of the participants had confirmed active TB and 26% were HIV co-infected. A no-go decision was taken regarding the whole blood MTB stimulated culture signature as low sensitivity (75 - 80%) with specificity of 86% was deemed insufficient for further development and as an overnight assay is not suitable for rapid point of care (POC) testing. However, a promising serum host inflammatory signature was identified during this project after investigation of more than 70 serum host inflammation markers, including acute phase proteins, T helper cell 1, T helper cell 2 and regulatory cytokines, soluble cytokine receptors and growth factors. The original set of markers for screening were chosen according to the availability of multiplexed assays (Luminex platform) and their known roles in inflammation and represented a wide spectrum of markers with diagnostic potential. The most promising host serum protein signature was subsequently validated on 687 people from five African countries with suspected TB, regardless of HIV infection status or ethnicity, providing the basis for the follow-up work suggested herein. The six-analyte signature of C-reactive protein (CRP), Interferon gamma (IFN-γ), pre-albumin, complement factor H (CFH), apolipoprotein A1 and inducible protein 10 (IP-10) ascertained TB disease with a sensitivity of 89% (CI 78 – 95%) and specificity of 76% (CI 68 – 83%), (positive predictive value of 61%; negative predictive value of 94%) ([7], [8]). Measurement of multiple markers and evaluation of their ratios offset a lack of disease specificity of individual markers. These performance characteristics would constitute a valuable screening test if converted into an inexpensive POC test and would prioritize individuals with a high likelihood of active TB for confirmatory testing by GeneXpert. During the AE-TBC pro...

Related to SCIENTIFIC RATIONALE

  • Investment Analysis and Commentary The Subadviser will provide quarterly performance analysis and market commentary (the “Investment Report”) during the term of this Agreement. The Investment Reports are due within 10 days after the end of each quarter. In addition, interim Investment Reports shall be issued at such times as may be mutually agreed upon by the Adviser and Subadviser; provided however, that any such interim Investment Report will be due within 10 days of the end of the month in which such agreement is reached between the Adviser and Subadviser. The subject of each Investment Report shall be mutually agreed upon. The Adviser is freely able to publicly distribute the Investment Report.

  • Infrastructure Vulnerability Scanning Supplier will scan its internal environments (e.g., servers, network devices, etc.) related to Deliverables monthly and external environments related to Deliverables weekly. Supplier will have a defined process to address any findings but will ensure that any high-risk vulnerabilities are addressed within 30 days.

  • Scientific Publications During the Research Program Term, neither Party shall first publish or first present in a public forum the scientific or technical results of any activity performed pursuant to this Agreement without the opportunity for prior review and comment by the other Party. Each Party agrees to provide the other Party with the opportunity to review any proposed abstract, manuscript or scientific presentation (including any verbal presentation) that relates to its activities performed pursuant to this Agreement during the Research Program Term, at least [**] days prior to its intended submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time up to [**] to secure patent protection for any material in such publication that it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications first with respect to activities performed or results obtained pursuant to this Agreement during the Research Program Term, or not to publish at all if necessary to preserve trade secrets. The Parties agree to review and decide whether to delay publication of such information to permit filing of patent applications. Neither Party shall have the right to publish or present any Confidential Information of the other Party, except as provided in Section 9.2. After the Research Program Term, each Party and its Affiliates may publish or present results, data or scientific findings of any of their activities without the prior review of the other Party, provided that such publication or presentation does not disclose any of the other Party’s Confidential Information. Nothing contained in this Section 9.3 shall prohibit the inclusion of information necessary for a patent application; provided that the non-filing Party is given a reasonable opportunity to review the information to be included prior to submission of such patent application in accordance with Section 8.2. Nothing contained in this Section 9.3 shall prohibit either Party from disclosing the results, data or scientific findings of any activity performed by the other Party or its Affiliates pursuant to this Agreement without prior review and prior written consent of the other Party, where required, as reasonably determined by the disclosing Party’s legal counsel, by applicable law; provided that if a Party is required by law to make any such disclosure, to the extent it may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise).

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order. (b) The technical evaluation committee may call the responsive bidders for discussion or presentation to facilitate and assess their understanding of the scope of work and its execution. However, the committee shall have sole discretion to call for discussion / presentation. (c) Financial bids of only those bidders who qualify the technical criteria will be opened provided all other requirements are fulfilled. (d) AIIMS Jodhpur shall have right to accept or reject any or all tenders without assigning any reasons thereof.

  • PROFESSIONAL DEVELOPMENT AND EDUCATIONAL IMPROVEMENT A. Both the Board and the Association encourage teachers to seek professional improvement. In order to assist teachers in extending and improving their skills the following plan will be implemented. B. All Teachers will be encouraged to earn a Masters degree or coursework toward additional certification that is in the field of education and within a teacher's discipline, or in an area that is beneficial to the school. C. The Board will pay teacher's expenses for undergraduate and/or graduate credits, specialty and additional endorsements under the following conditions. 1. In allocating budgeted funds priority will be given to the teachers in a “masters” program and those teachers who need to complete coursework for certification. 2. All courses must be approved, in advance, by the Superintendent. Courses for recertification purposes must be approved in advance by the certification committee and the superintendent. The teacher shall receive a written reply from the Superintendent within ten (10) days of application for course approval (See Appendix D). 3. Each teacher will be eligible for up to six (6) semester hours of credit or, if enrolled in a matriculated, organized program, 12 semester hours of credit for undergraduate will be paid if part of a graduate program or graduate courses per contract year. The Superintendent reserves the right to request intent to take courses prior to final budget preparation. Failure to communicate such intent at the time of the Superintendent’s request may jeopardize course reimbursement due to a lack of funding. 4. The administration will pay in advance the cost of the course. Presentation of evidence of satisfactory completion of the course (A grade of B or better) is the responsibility of the teacher. In the event the course is not completed or not completed satisfactorily, the teacher will refund the payment received in advance and in accordance with Appendix D – attached. 5. Teachers who resign shall not be eligible for reimbursement after the date of resignation Teachers who have been reimbursed for any course work toward securing a masters within the last two (2) years of employment shall be required to continue their service to RSU # 78 for an additional two (2) years (twenty-four months) or will be required to reimburse the district the cost associated with Masters courses taken prior to departing, Such reimbursement to the district shall be remitted via payroll deductions as arranged between the District and employee, unless the failure to continue employment is due to illness, disability, death, or reduction of position. 6. Reimbursement will only be for tuition and fees. It will not include reimbursement for mileage, books and other expenses unless the teacher is required to take the course by the administration.